Open Access

ARTICLE

Identification of Circular RNA hsa-circ-0006969 as a Novel Biomarker for Breast Cancer

Libin Wang^1,2,3,#, Xiaohan Li^1,3,#, Jinhai Tian^1,2,3, Jingjing Yu^1,2,3, Qi Huang^1,2,3, Rong Ma^1,2,3, Jia Wang^1,2,3, Jia Cao^1,2,3, Jinping Li^4,*, Xu Zhang^1,2,3,*

1 Department of Beijing National Biochip Research Center Sub-Center in Ningxia, General Hospital of Ningxia Medical University, Yinchuan, 750004, China
2 College of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, China
3 Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, 750004, China
4 Department of Oncological Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China

* Corresponding Authors: Jinping Li. Email: ; Xu Zhang. Email:

(This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)

Oncologie 2022, 24(4), 789-801. https://doi.org/10.32604/oncologie.2022.026589

Received 14 September 2022; Accepted 08 December 2022; Issue published 31 December 2022

Abstract

Background: To investigate the characteristics of circular RNA hsa-circ-0006969 in breast cancer and identify it as a novel biomarker for breast cancer. Methods: Three breast cancer (BC) patient tissues were selected to perform human circRNA microarray analysis. GeneSpring 13.0 (Agilent) software was applied for analyzing the data. Another 116 BC patients were recruited for verification. Hsa-circ-0006969 was found as a potential circRNA for BC diagnostic biomarker. The structure of hsa-circ-0006969 was predicted by circPrimer1.2 software. MiRanda v3.3, RNA hybrid 2.1, and Cytoscape 3.6.0 were used for predicting the networks of circRNA-miRNA. T-test, Curve regression, and ROC analysis were applied to certify the diagnostic values of hsa-circ-0006969. Using SPSS25.0 software to perform the Statistical analysis. Results: 546 higher expression and 1475 lower expression circRNAs were identified. Four circRNAs were filtrated for further verification. Hsa-circ-0006969 was significantly low expressed in BC tissues and peripheral blood. Hsa-circ-0006969 was confirmed as higher diagnostic correlation with BC tissues (AUC = 0.965) and peripheral blood (AUC = 0.842), with Grade 1 (AUC = 0.639), ER-positive (AUC = 0.612), TNM I (AUC = 0.693), TNM II (AUC = 0.712), TNM III (AUC = 0.757), TNM early stage(I, II) (AUC = 0.709). Hsa-circ-0006969 presented more effective diagnostic values for tumor metastasis (AUC = 0.784) compared with CA153 (AUC = 0.752). Conclusion: Hsa-circ-0006969 could be a novel biomarker for the diagnosis and treatment of BC.

---

Keywords

---

Supplementary Material

Supplementary Material File

---